content

Novavax, Inc. , a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced enrollment of the first participants in a Phase 1/2...

The U.S. FDA approved Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with...

Thermo Fisher Scientific, the world leader in serving science, and Biognosys, a leading developer of next-generation proteomics solutions, announce they are continuing their collaboration...

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory...

Merck announced on May 26 that it has entered an agreement to acquire privately held Themis, a company that is developing a vaccine candidate...

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced that the companies have...

Glenmark Pharmaceuticals announced on Tuesday that it will commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and...